Acetylcholinesterase inhibitors combined with memantine for moderate to severe Alzheimer's disease: a meta-analysis
BACKGROUND The clinical efficacy and safety of combination therapy with acetylcholinesterase inhibitor (AChEI) and memantine compared to AChEI or memantine alone in patients with Alzheimer’s disease is inconclusive. AIMS OF THE STUDY. We conducted a systematic review and meta...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SMW supporting association (Trägerverein Swiss Medical Weekly SMW)
2019-06-01
|
| Series: | Swiss Medical Weekly |
| Subjects: | |
| Online Access: | https://www.smw.ch/index.php/smw/article/view/2635 |
| _version_ | 1811289007455207424 |
|---|---|
| author | Dominik Glinz Viktoria L. Gloy Andreas U. Monsch Reto W. Kressig Chandni Patel Kimberly Alba McCord Zanfina Ademi Yuki Tomonaga Matthias Schwenkglenks Heiner C. Bucher Heike Raatz |
| author_facet | Dominik Glinz Viktoria L. Gloy Andreas U. Monsch Reto W. Kressig Chandni Patel Kimberly Alba McCord Zanfina Ademi Yuki Tomonaga Matthias Schwenkglenks Heiner C. Bucher Heike Raatz |
| author_sort | Dominik Glinz |
| collection | DOAJ |
| description |
BACKGROUND
The clinical efficacy and safety of combination therapy with acetylcholinesterase inhibitor (AChEI) and memantine compared to AChEI or memantine alone in patients with Alzheimer’s disease is inconclusive.
AIMS OF THE STUDY. We conducted a systematic review and meta-analysis of randomised controlled trials (RCTs) comparing the clinical efficacy and safety of combination therapy of AChEI and memantine to monotherapy with either substance in patients with moderate to severe Alzheimer's disease (Mini-Mental State Examination score is <20).
METHODS
We systematically searched EMBASE, Medline and CENTRAL until February 2018 for eligible RCTs. We pooled the outcome data using inverse variance weighting models assuming random effects, and assessed the quality of evidence (QoE) according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE).
RESULTS
We included nine RCTs (2604 patients). At short-term follow-up (closest to 6 months), combination therapy compared to AChEI monotherapy had a significantly greater effect on cognition than AChEI monotherapy (standardised mean difference [SMD] 0.20, 95% confidence interval [CI] 0.05 to 0.35, 7 RCTs, low QoE) and clinical global impression (SMD −0.15, 95% CI −0.28 to −0.01, 4 RCTs, moderate QoE), but not on activities of daily living (SMD 0.09, 95% CI −0.01 to 0.18, 5 RCTs, moderate QoE) or behavioural and psychological symptoms of dementia (mean difference −3.07, 95% CI −6.53 to 0.38, 6 RCT, low QoE). There was no significant difference in adverse events (relative risk ratio 1.05, 95% CI 0.98 to 1.12, 4 RCTs, low QoE). Evidence for long-term follow-up (≥ 9 months) or nursing home placement was sparse. Only two studies compared combination therapy with memantine monotherapy.
CONCLUSIONS
Combination therapy had statistically significant effects on cognition and clinical global impression. The clinical relevance of these effects is uncertain. The overall QoE was very low. With the current evidence, it remains unclear whether combination therapy adds any benefit. Large pragmatic RCTs with long-term follow-up and focus on functional outcomes, delay in nursing home placement and adverse events are needed.
|
| first_indexed | 2024-04-13T03:47:21Z |
| format | Article |
| id | doaj.art-d9936ee4f7da47508182596ab967a067 |
| institution | Directory Open Access Journal |
| issn | 1424-3997 |
| language | English |
| last_indexed | 2024-04-13T03:47:21Z |
| publishDate | 2019-06-01 |
| publisher | SMW supporting association (Trägerverein Swiss Medical Weekly SMW) |
| record_format | Article |
| series | Swiss Medical Weekly |
| spelling | doaj.art-d9936ee4f7da47508182596ab967a0672022-12-22T03:03:59ZengSMW supporting association (Trägerverein Swiss Medical Weekly SMW)Swiss Medical Weekly1424-39972019-06-01149252610.4414/smw.2019.20093Acetylcholinesterase inhibitors combined with memantine for moderate to severe Alzheimer's disease: a meta-analysisDominik Glinz0Viktoria L. Gloy1Andreas U. Monsch2Reto W. Kressig3Chandni Patel4Kimberly Alba McCord5Zanfina Ademi6Yuki Tomonaga7Matthias Schwenkglenks8Heiner C. Bucher9Heike Raatz10Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel and University of Basel, SwitzerlandBasel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel and University of Basel, SwitzerlandMemory Clinic, University Centre for Medicine of Aging, Felix Platter Hospital and University of Basel, SwitzerlandUniversity Centre for Medicine of Ageing, Felix Platter Hospital, and University of Basel, SwitzerlandBasel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel and University of Basel, SwitzerlandBasel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel and University of Basel, SwitzerlandInstitute of Pharmaceutical Medicine, University of Basel, Switzerland; School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia,Epidemiology, Biostatistics and Prevention Institute, University of Zurich, SwitzerlandSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Australia,; Epidemiology, Biostatistics and Prevention Institute, University of Zurich, SwitzerlandBasel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel and University of Basel, SwitzerlandInstitute of Pharmaceutical Medicine, University of Basel, Switzerland; Kleijnen Systematic Reviews Ltd., Escrick, York, United Kingdom BACKGROUND The clinical efficacy and safety of combination therapy with acetylcholinesterase inhibitor (AChEI) and memantine compared to AChEI or memantine alone in patients with Alzheimer’s disease is inconclusive. AIMS OF THE STUDY. We conducted a systematic review and meta-analysis of randomised controlled trials (RCTs) comparing the clinical efficacy and safety of combination therapy of AChEI and memantine to monotherapy with either substance in patients with moderate to severe Alzheimer's disease (Mini-Mental State Examination score is <20). METHODS We systematically searched EMBASE, Medline and CENTRAL until February 2018 for eligible RCTs. We pooled the outcome data using inverse variance weighting models assuming random effects, and assessed the quality of evidence (QoE) according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE). RESULTS We included nine RCTs (2604 patients). At short-term follow-up (closest to 6 months), combination therapy compared to AChEI monotherapy had a significantly greater effect on cognition than AChEI monotherapy (standardised mean difference [SMD] 0.20, 95% confidence interval [CI] 0.05 to 0.35, 7 RCTs, low QoE) and clinical global impression (SMD −0.15, 95% CI −0.28 to −0.01, 4 RCTs, moderate QoE), but not on activities of daily living (SMD 0.09, 95% CI −0.01 to 0.18, 5 RCTs, moderate QoE) or behavioural and psychological symptoms of dementia (mean difference −3.07, 95% CI −6.53 to 0.38, 6 RCT, low QoE). There was no significant difference in adverse events (relative risk ratio 1.05, 95% CI 0.98 to 1.12, 4 RCTs, low QoE). Evidence for long-term follow-up (≥ 9 months) or nursing home placement was sparse. Only two studies compared combination therapy with memantine monotherapy. CONCLUSIONS Combination therapy had statistically significant effects on cognition and clinical global impression. The clinical relevance of these effects is uncertain. The overall QoE was very low. With the current evidence, it remains unclear whether combination therapy adds any benefit. Large pragmatic RCTs with long-term follow-up and focus on functional outcomes, delay in nursing home placement and adverse events are needed. https://www.smw.ch/index.php/smw/article/view/2635Alzheimer’scholinesterase inhibitordementiadrug treatmentmemantine |
| spellingShingle | Dominik Glinz Viktoria L. Gloy Andreas U. Monsch Reto W. Kressig Chandni Patel Kimberly Alba McCord Zanfina Ademi Yuki Tomonaga Matthias Schwenkglenks Heiner C. Bucher Heike Raatz Acetylcholinesterase inhibitors combined with memantine for moderate to severe Alzheimer's disease: a meta-analysis Swiss Medical Weekly Alzheimer’s cholinesterase inhibitor dementia drug treatment memantine |
| title | Acetylcholinesterase inhibitors combined with memantine for moderate to severe Alzheimer's disease: a meta-analysis |
| title_full | Acetylcholinesterase inhibitors combined with memantine for moderate to severe Alzheimer's disease: a meta-analysis |
| title_fullStr | Acetylcholinesterase inhibitors combined with memantine for moderate to severe Alzheimer's disease: a meta-analysis |
| title_full_unstemmed | Acetylcholinesterase inhibitors combined with memantine for moderate to severe Alzheimer's disease: a meta-analysis |
| title_short | Acetylcholinesterase inhibitors combined with memantine for moderate to severe Alzheimer's disease: a meta-analysis |
| title_sort | acetylcholinesterase inhibitors combined with memantine for moderate to severe alzheimer s disease a meta analysis |
| topic | Alzheimer’s cholinesterase inhibitor dementia drug treatment memantine |
| url | https://www.smw.ch/index.php/smw/article/view/2635 |
| work_keys_str_mv | AT dominikglinz acetylcholinesteraseinhibitorscombinedwithmemantineformoderatetoseverealzheimersdiseaseametaanalysis AT viktorialgloy acetylcholinesteraseinhibitorscombinedwithmemantineformoderatetoseverealzheimersdiseaseametaanalysis AT andreasumonsch acetylcholinesteraseinhibitorscombinedwithmemantineformoderatetoseverealzheimersdiseaseametaanalysis AT retowkressig acetylcholinesteraseinhibitorscombinedwithmemantineformoderatetoseverealzheimersdiseaseametaanalysis AT chandnipatel acetylcholinesteraseinhibitorscombinedwithmemantineformoderatetoseverealzheimersdiseaseametaanalysis AT kimberlyalbamccord acetylcholinesteraseinhibitorscombinedwithmemantineformoderatetoseverealzheimersdiseaseametaanalysis AT zanfinaademi acetylcholinesteraseinhibitorscombinedwithmemantineformoderatetoseverealzheimersdiseaseametaanalysis AT yukitomonaga acetylcholinesteraseinhibitorscombinedwithmemantineformoderatetoseverealzheimersdiseaseametaanalysis AT matthiasschwenkglenks acetylcholinesteraseinhibitorscombinedwithmemantineformoderatetoseverealzheimersdiseaseametaanalysis AT heinercbucher acetylcholinesteraseinhibitorscombinedwithmemantineformoderatetoseverealzheimersdiseaseametaanalysis AT heikeraatz acetylcholinesteraseinhibitorscombinedwithmemantineformoderatetoseverealzheimersdiseaseametaanalysis |